Plasma Only Circulating Tumor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Plasma only circulating tumor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Plasma Only Circulating Tumor Today - Breaking & Trending Today

Natera Responds to Meritless Lawsuit and Files False Advertising Claim Against Guardant for Misleading Oncologists

Natera Responds to Meritless Lawsuit and Files False Advertising Claim Against Guardant for Misleading Oncologists
News provided by
Share this article
Share this article
AUSTIN, Texas, May 28, 2021 /PRNewswire/ Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it has been sued by Guardant Health, in an attempt to stop Natera from exposing Guardant Reveal s™ true test performance and the differences between tumor-informed and tumor-naive molecular residual disease (MRD) tests.
Natera has filed a claim against Guardant in the U.S. District Court for the Western District of Texas, (Docket No.6:21-cv-00540), alleging that Guardant used false and misleading claims to deceive physicians about the performance capabilities of its MRD test, in violation of the Lanham Act. Guardant s MRD test performance claims are incomplete or unsupported by clinical evidence, and can be misinterpreted by physicians and pat ....

United States , San Carlos , Mike Brophy , Kate Stabrawa , Natera Inc , Guardant Health , Clinical Laboratory Improvement Amendments , Us District Court , Clinical Cancer Research , Guardant Reveal , Western District , Healthcare Conference , Residual Disease Detection , Plasma Only Circulating Tumor , Colorectal Cancer , Clinical Cancer , ஒன்றுபட்டது மாநிலங்களில் , சான் கார்லோஸ் , மைக் கோப்பை , மருத்துவ ஆய்வகம் முன்னேற்றம் திருத்தங்கள் , எங்களுக்கு மாவட்டம் நீதிமன்றம் , மருத்துவ புற்றுநோய் ஆராய்ச்சி , மேற்கு மாவட்டம் , சுகாதாரம் மாநாடு , பெருங்குடல் புற்றுநோய் , மருத்துவ புற்றுநோய் ,

Researchers Evaluate the First "Tumor-Uninformed" Test That Detects Cancer DNA Post-Surgery

A recurrence occurs when cancer comes back after treatment. This can happen weeks, months, or even years after the primary or original cancer was treated. It is impossible to know for sure if the cancer will recur and timely detection of recurrence, as well as identification of patients at high risk of recurrence after surgery, can be challenging. Postsurgical circulating tumor DNA (ctDNA) analysis is a promising tool for the identification of patients with minimal residual disease. Now researchers at Massachusetts General Hospital (MGH) report they have evaluated the first test that detects cancer DNA circulating in the blood of patients following treatment without knowing the particular mutations that were present in the patient’s tumor. ....

United States , Aparnar Parikh , Guardant Health , Harvard Medical School , Clinical Cancer Research , Massachusetts General Hospital , Residual Disease Detection , Plasma Only Circulating Tumor , Colorectal Cancer Patients , Guardant Reveal , Harvard Medical , ஒன்றுபட்டது மாநிலங்களில் , ஹார்வர்ட் மருத்துவ பள்ளி , மருத்துவ புற்றுநோய் ஆராய்ச்சி , மாசசூசெட்ஸ் ஜநரல் மருத்துவமனை , பெருங்குடல் புற்றுநோய் நோயாளிகள் , ஹார்வர்ட் மருத்துவ ,